Improving the Pharmacological Properties of Ciclopirox for Its Use in Congenital Erythropoietic Porphyria

Improving the Pharmacological Properties of Ciclopirox for Its Use in Congenital Erythropoietic Porphyria

Congenital erythropoietic porphyria (CEP), also known as Günther’s disease, results from a deficient activity in the fourth enzyme, uroporphyrinogen III synthase (UROIIIS), of the heme pathway. Ciclopirox (CPX) is an off-label drug, topically prescribed as an antifungal. It has been recently shown t...

Full description

Bibliographic Details
Main Authors: Ganeko Bernardo-Seisdedos, Jorge M. Charco, Itxaso SanJuan, Sandra García-Martínez, Pedro Urquiza, Hasier Eraña, Joaquín Castilla, Oscar Millet
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Journal of Personalized Medicine
Subjects:
ciclopirox
pharmacological chaperones
porphyria
drug discovery
protein stability
Online Access:https://www.mdpi.com/2075-4426/11/6/485

Internet

https://www.mdpi.com/2075-4426/11/6/485

Similar Items